BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 20392512)

  • 1. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
    Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
    J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis.
    Musso G; Gambino R; Cassader M
    J Nutr Biochem; 2010 Sep; 21(9):834-40. PubMed ID: 19733470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
    García-Monzón C; Lo Iacono O; Mayoral R; González-Rodríguez A; Miquilena-Colina ME; Lozano-Rodríguez T; García-Pozo L; Vargas-Castrillón J; Casado M; Boscá L; Valverde AM; Martín-Sanz P
    J Hepatol; 2011 Jan; 54(1):142-52. PubMed ID: 20888662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease.
    Pereira IV; Stefano JT; Oliveira CP
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):245-51. PubMed ID: 21476919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis.
    Perlemuter G; Sabile A; Letteron P; Vona G; Topilco A; Chrétien Y; Koike K; Pessayre D; Chapman J; Barba G; Bréchot C
    FASEB J; 2002 Feb; 16(2):185-94. PubMed ID: 11818366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R; Cassader M; Pagano G; Durazzo M; Musso G
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice.
    Lettéron P; Sutton A; Mansouri A; Fromenty B; Pessayre D
    Hepatology; 2003 Jul; 38(1):133-40. PubMed ID: 12829995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.
    Matsuzawa N; Takamura T; Kurita S; Misu H; Ota T; Ando H; Yokoyama M; Honda M; Zen Y; Nakanuma Y; Miyamoto K; Kaneko S
    Hepatology; 2007 Nov; 46(5):1392-403. PubMed ID: 17929294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
    Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
    Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V; Lucero D; Macri EV; Cacciagiú L; Gamba CA; Miksztowicz V; Berg G; Wikinski R; Friedman S; Schreier L
    Ann Nutr Metab; 2010; 56(3):198-206. PubMed ID: 20203480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
    Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
    J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
    Ariz U; Mato JM; Lu SC; Martínez Chantar ML
    Methods Mol Biol; 2010; 593():109-36. PubMed ID: 19957147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
    VerHague MA; Cheng D; Weinberg RB; Shelness GS
    Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.